论文部分内容阅读
目的探讨莫西沙星序贯疗法治疗慢性阻塞性肺疾病(COPD)急性加重期可行性。方法 COPD急性加重期患者随机分及观察组对照组各60例,两组均给予综合治疗,对照组应用盐酸莫西沙星氯化钠注射液0.4g,1次/d,静脉滴注,持续静脉用药。观察组静脉滴注莫西沙星3~5 d,体温正常、外周血白细胞正常、病情稳定改为口服莫西沙星胶囊。结果观察组总有效率96.67%与对照组的95.00%无差异(P>0.05),观察组药物不良反应40.00%低于对照组的46.67%(P<0.05)。结论莫西沙星序贯疗法治疗COPD急性加重期具有可行性。
Objective To investigate the feasibility of sequential therapy of moxifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 60 patients with acute exacerbation of COPD were randomly divided into observation group and control group with 60 cases in each group. All patients in the control group were treated with moxifloxacin sodium chloride injection 0.4g, once daily, intravenous drip, Medication. Observation group intravenous drip moxifloxacin 3 ~ 5 d, normal body temperature, normal peripheral white blood cells, stable condition changed to oral moxifloxacin capsules. Results The total effective rate was 96.67% in the observation group and 95.00% in the control group (P> 0.05). The adverse drug reaction rate in the observation group was 40.6% lower than that in the control group (46.67%, P <0.05). Conclusion sequential treatment of moxifloxacin in the treatment of acute exacerbation of COPD is feasible.